Novartis/$NVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis Metrics
BasicAdvanced
$236B
17.88
$6.85
0.53
$2.60
2.12%
Price and volume
Market cap
$236B
Beta
0.53
52-week high
$130.46
52-week low
$96.06
Average daily volume
1.2M
Dividend rate
$2.60
Financial strength
Current ratio
0.818
Quick ratio
0.502
Long term debt to equity
57.222
Total debt to equity
77.607
Dividend payout ratio (TTM)
57.26%
Interest coverage (TTM)
17.47%
Profitability
EBITDA (TTM)
23,552
Gross margin (TTM)
76.28%
Net profit margin (TTM)
24.74%
Operating margin (TTM)
34.76%
Effective tax rate (TTM)
12.62%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
11.88%
Return on equity (TTM)
32.49%
Valuation
Price to earnings (TTM)
17.879
Price to revenue (TTM)
4.39
Price to book
4.45
Price to tangible book (TTM)
-14.6
Price to free cash flow (TTM)
14.365
Free cash flow yield (TTM)
6.96%
Free cash flow per share (TTM)
8.526
Dividend yield (TTM)
2.12%
Forward dividend yield
2.12%
Growth
Revenue change (TTM)
12.95%
Earnings per share change (TTM)
-12.59%
3-year revenue growth (CAGR)
4.33%
10-year revenue growth (CAGR)
0.70%
3-year earnings per share growth (CAGR)
-12.58%
10-year earnings per share growth (CAGR)
-1.49%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Bulls say / Bears say
Novartis raised its full-year 2025 core operating income growth forecast to a low-teens percentage after Q2 adjusted operating income rose 20% to $5.9 billion and sales climbed 12% to $14 billion, underpinned by strong demand for Kisqali, Kesimpta and Entresto. (Reuters)
Phase 3 data presented in late August showed that BAF312 reduced three-month confirmed disability progression in secondary progressive multiple sclerosis by 21% versus placebo, supporting analysts’ forecast of up to $3 billion in peak annual sales. (Reuters)
FDA approved Kisqali in March for first-line treatment of HR+/HER2- negative advanced breast cancer after trial results showed a 44% reduction in the risk of disease progression or death versus letrozole alone, positioning Novartis to challenge Pfizer’s Ibrance in a market exceeding $2 billion. (Reuters)
Novartis suffered a legal setback when a U.S. court denied its injunction to block a generic version of heart failure drug Entresto, with generic entry expected in H2 2025 to weigh on sales growth. (Reuters)
Beovu’s launch was initially sluggish after regulators in the U.S. and Europe issued safety warnings over rare cases of retinal vasculitis and vascular occlusion, prompting an external safety review that has delayed uptake. (Reuters)
Novartis pushed back completion of a large UK outcomes study for cholesterol drug Leqvio to 2026 due to COVID-19 recruitment delays, deferring key efficacy data needed for broader adoption. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $236B as of September 18, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 17.88 as of September 18, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $2.59609 and the yield is 2.12%. Novartis has a payout ratio of 57.26% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.